{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:10:56Z","timestamp":1791144656629,"version":"4.1.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1097\/cji.0b013e31817fd90b","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T18:18:41Z","timestamp":1236277121000},"page":"591-598","source":"Crossref","is-referenced-by-count":72,"title":["Phase Ib Trial Assessing Autologous, Tumor-pulsed Dendritic Cells as a Vaccine Administered With or Without IL-2 in Patients With Metastatic Melanoma"],"prefix":"10.1097","volume":"31","author":[{"given":"Bruce G.","family":"Redman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred E.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Whitfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peg","family":"Esper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Mul\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210219","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"R2-9-20210219","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1084\/jem.180.1.83","article-title":"Proliferating dendritic cell progenitors in human blood","volume":"180","author":"Romani","year":"1994","journal-title":"J Exp Med"},{"key":"R3-9-20210219","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide or tumor lysate pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"},{"key":"R4-9-20210219","first-page":"1021","article-title":"A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer","volume":"8","author":"Chang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R5-9-20210219","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1073\/pnas.96.5.2268","article-title":"Systemic administration of interleukin-2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines","volume":"96","author":"Shimizu","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-9-20210219","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1200\/JCO.1997.15.2.796","article-title":"Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated anti-CD3 and interleukin-2","volume":"15","author":"Chang","year":"1997","journal-title":"J Clin Oncol"},{"key":"R7-9-20210219","first-page":"1","article-title":"Role of dendritic cells in cancer immunotherapy","volume":"1","author":"Palucka","year":"2007","journal-title":"PPO Focus Cancer Immunol"},{"key":"R8-9-20210219","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.4.5.699","article-title":"Dendritic cells: Tools and targets for antitumor vaccination","volume":"4","author":"den Brok","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"R9-9-20210219","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.cji.0000171314.00924.2b","article-title":"Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2","volume":"28","author":"Chianese-Bullock","year":"2005","journal-title":"J Immunother"},{"key":"R10-9-20210219","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2249.2005.02948.x","article-title":"Dendritic cell immunization alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients","volume":"105","author":"Escobar","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"R11-9-20210219","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1200\/JCO.1988.6.9.1440","article-title":"Acute immunological effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigen","volume":"6","author":"Wiebke","year":"1998","journal-title":"J Clin Oncol"},{"key":"R12-9-20210219","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumor microenvironment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R13-9-20210219","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1084\/jem.194.6.823","article-title":"Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternate pathways for suppression of autoreactive cytotoxic T lymphocyte responses","volume":"194","author":"Sutmuller","year":"2001","journal-title":"J Exp Med"},{"key":"R14-9-20210219","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Cancer Res"},{"key":"R15-9-20210219","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI25947","article-title":"Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells","volume":"115","author":"Dannull","year":"2005","journal-title":"J Clin Invest"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CJI.0b013e31817fd90b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T07:43:51Z","timestamp":1684914231000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002371-200807000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e31817fd90b","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}